معرفی
Charles Hart is the Executive Director of the Catalyst Program through Innovation Ventures at the University of California, San Francisco (UCSF). He holds the title of Adjunct Professor in Pharmaceutical Chemistry and has maintained an active role in academic research through his work on hypoxia-activated prodrugs and their applications in oncology.
- University of California, Berkeley: AB in Cell Biology (1977)
- Stanford University: MS in Developmental Biology (1980)
- Yale University: PhD in Molecular Biology and Genetics (1987)
- Université de Strasbourg, France: Postdoctoral fellowship in Molecular Biology (1990)
Hart's research focuses on hypoxia-activated prodrugs like TH-302, targeting tumor hypoxia in cancers including glioblastoma, pancreatic cancer, and multiple myeloma. His work explores drug mechanisms, combination therapies with radiation, and biomarkers for treatment response. Publications emphasize neoplasms, pharmacology, and molecular biology, with collaborations across hematology, neurology, and radiology.
Key trends in his publications include hypoxia targeting in preclinical models and clinical trial frameworks. Hart has published extensively on evofosfamide (TH-302) across 2012-2024, with a focus on drug synergy with radiation, mitochondrial oxygen consumption, and tumor microenvironment dynamics.
Hart's contributions include laboratory leadership in pharmaceutical chemistry and translational oncology, with a strong emphasis on drug development and preclinical evaluation. His work has been cited in PubMed Central, Wikipedia, and referenced in patents related to chemotherapy agents.
